Compare SOAR & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOAR | XRTX |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Blank Checks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.4M |
| IPO Year | N/A | N/A |
| Metric | SOAR | XRTX |
|---|---|---|
| Price | $0.56 | $0.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 32.9K |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $58,312,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.35 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.41 | $0.51 |
| 52 Week High | $6.48 | $1.41 |
| Indicator | SOAR | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.59 | 38.46 |
| Support Level | $0.41 | $0.52 |
| Resistance Level | $0.73 | $0.60 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 39.57 | 17.50 |
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.